Johnson & Johnson(JNJ)
Drug Manufacturers - General · New Brunswick, NJ
$265.58-0.77 (-0.29%)
Delayed quote: Sep 11, 2026, 4:00 PM EDT
Drug Manufacturers - General · New Brunswick, NJ
Delayed quote: Sep 11, 2026, 4:00 PM EDT
Trailing-twelve-month (TTM) net income is $21.04 Billion with a year-over-year change of (7.17%). Net income represents the company's bottom line profit after all expenses, taxes, and interest.
Reported quarterly net income; no daily interpolation. Q2 FY2026 (2026-06-28): $5.53B.
Net Income growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-09-14T13:20:46.727Z. Historical observations retain their original dates. Historical series through 2026-09-11.
$21.04B
$21.04 Billion
(7.17%)
vs. $22.66B a year ago (TTM)
+6.52%
5 Year compound annual growth rate
1 Year
(7.17%)
3 Year
+16.79%
5 Year
+6.52%
10 Year
+3.00%
15 Year
+3.59%
20 Year
+3.44%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Net Income | YoY Change | % Change |
|---|---|---|---|
| 2025 | $26.80B | +$12.74B | +90.56% |
| 2024 | $14.07B | ($21.09B) | (59.99%) |
| 2023 | $35.15B | +$17.21B | +95.94% |
| 2022 | $17.94B | ($2.94B) | (14.07%) |
| 2021 | $20.88B | +$6.16B | +41.89% |
| 2020 |
TTM Growth
(7.17%)
3-Year CAGR
+16.79%
5-Year CAGR
+6.52%
Unrounded diluted TTM EPS / FMP quote price × 100 Quote observation: 2026-09-14T13:20:46.727Z. Historical observations retain their original dates. Historical series through 2026-09-11.
| $14.71B |
| ($405.00M) |
| (2.68%) |
| 2019 | $15.12B | ($178.00M) | (1.16%) |
| 2018 | $15.30B | +$14.00B | +1076.69% |
| 2017 | $1.30B | ($15.24B) | (92.14%) |
| 2016 | $16.54B | +$1.13B | +7.34% |